- Home
- MYND vs GNLX Comparison
MYND vs GNLX Comparison
Compare MYND & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYND
- GNLX
- Stock Information
- Founded
- MYND 1998
- GNLX 2001
- Country
- MYND Cayman Islands
- GNLX United States
- Employees
- MYND N/A
- GNLX N/A
- Industry
- MYND Other Consumer Services
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- MYND Real Estate
- GNLX Health Care
- Exchange
- MYND Nasdaq
- GNLX Nasdaq
- Market Cap
- MYND 121.0M
- GNLX 103.6M
- IPO Year
- MYND 2017
- GNLX 2023
- Fundamental
- Price
- MYND $1.87
- GNLX $2.40
- Analyst Decision
- MYND
- GNLX Strong Buy
- Analyst Count
- MYND 0
- GNLX 4
- Target Price
- MYND N/A
- GNLX $18.25
- AVG Volume (30 Days)
- MYND 109.3K
- GNLX 163.2K
- Earning Date
- MYND 02-05-2025
- GNLX 11-14-2024
- Dividend Yield
- MYND N/A
- GNLX N/A
- EPS Growth
- MYND N/A
- GNLX N/A
- EPS
- MYND N/A
- GNLX N/A
- Revenue
- MYND $357,050,000.00
- GNLX $8,000.00
- Revenue This Year
- MYND N/A
- GNLX N/A
- Revenue Next Year
- MYND N/A
- GNLX N/A
- P/E Ratio
- MYND N/A
- GNLX N/A
- Revenue Growth
- MYND N/A
- GNLX N/A
- 52 Week Low
- MYND $0.61
- GNLX $1.60
- 52 Week High
- MYND $6.95
- GNLX $16.60
- Technical
- Relative Strength Index (RSI)
- MYND 46.89
- GNLX 40.85
- Support Level
- MYND $2.06
- GNLX $2.48
- Resistance Level
- MYND $2.60
- GNLX $2.80
- Average True Range (ATR)
- MYND 0.49
- GNLX 0.20
- MACD
- MYND -0.06
- GNLX -0.04
- Stochastic Oscillator
- MYND 3.40
- GNLX 15.38
About MYND Mynd.ai Inc.
Mynd.ai Inc is a company that provides a platform for delivering digital content in K-12 classrooms, giving teachers seamless connectivity to inspire young minds. It features agnostic hardware that integrates across technology providers. Its product line includes a wide range of interactive tools and technologies, with its award-winning interactive displays at the forefront. It also offers interactive software apps such as Screen Share, computing modules, and accessories that meet the needs of customers, including K -12 educators, colleges and universities, small businesses and corporations, government agencies, and more.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.